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Consider these medications  
to help patients stay sober
Naltrexone can help prevent relapse in recently 
detoxified patients with alcohol use disorder. The 
evidence for acamprosate is not quite as strong.
PRACTICE CHANGER
Consider prescribing oral naltrexone 
(50 mg/d) for patients with alcohol use disor-
der who wish to maintain abstinence after a 
brief period of detoxification.1 
StreNGtH oF reCoMMeNDAtioN
A: Based on a meta-analysis of 95 random-
ized controlled trials.
Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with 
alcohol use disorders in outpatient settings: a systematic review and 
meta-analysis. JAMA. 2014;311:1889-1900.
ILLUSTRATIVE CASE
your patient, a 42-year-old man with alcohol 
use disorder (auD), detoxifies from alcohol 
during a recent hospitalization. he doesn’t 
want to resume drinking, but reports frequent 
cravings. are there any medications you can 
prescribe to help prevent relapse?
Excessive alcohol consumption is re-sponsible for 1 of every 10 deaths among US adults ages 20 to 64 years.2 
Twenty percent to 36% of patients seen in a 
primary care office have AUD.3 Up to 70% of 
people who quit with psychosocial support 
alone will relapse.3
The US Preventive Services Task Force 
gives a grade B recommendation to screening 
all adults for AUD, indicating that physicians 
should provide this service.4 For patients with 
AUD who wish to abstain but struggle with 
cravings and relapse, the National Institute 
on Alcohol Abuse and Alcoholism (NIAAA) 
recommends considering medication as an 
adjunct to brief behavioral counseling.5 
STUDY SUMMARY
evidence shows naltrexone  
can prevent a return to drinking 
In a meta-analysis, Jonas et al1 reviewed 
123 studies (N=22,803) of pharmacotherapy 
for AUD. After excluding 28 studies (7 were 
the only study of a given drug, one was a pro-
spective cohort, and 20 had insufficient data), 
95 randomized control trials were included 
in the analysis. Twenty-two were placebo- 
controlled for acamprosate (1000-3000 mg/d), 
44 for naltrexone (50 mg/d oral, 100 mg/d 
oral, or injectable) and 4 compared the 
2 drugs. Additional studies evaluated disulfi-
ram as well as 23 other off-label medications 
such as valproic acid and topiramate. 
Two investigators independently 
reviewed the studies, checking for complete-
ness and accuracy. Studies were also ana-
lyzed for bias using predefined criteria; those 
with high or unclear risk of bias were exclud-
ed from the main analysis but included in the 
sensitivity analysis. Funnel plots showed no 
evidence of publication bias. 
Participants were primarily recruited as 
inpatients and in most studies the mean age 
was in the 40s. Most patients were diagnosed 
with alcohol dependence based on criteria 
in the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition, text revision 
(DSM-IV-TR); this diagnosis translates to 
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likely moderate to severe AUD in DSM-5. 
Prior to starting medications, participants 
underwent detoxification or achieved at 
least 3 days of sobriety. Most studies includ-
ed psychosocial intervention in addition to 
medication, but the types of interventions 
varied. The duration of the trials ranged 
from 12 to 52 weeks.
Researchers analyzed 5 drinking out-
comes—return to any drinking, return to 
heavy drinking (defined as ≥4 drinks/d for 
women and ≥5 drinks/d for men), number 
of drinking days, number of heavy drinking 
days, and drinks per drinking day. They also 
evaluated health outcomes (accidents, inju-
ries, quality of life, function, and mortality) 
and adverse effects. 
Acamprosate and oral naltrexone 
(50 mg/d) significantly decreased return 
to any drinking, with a number needed 
to treat (NNT) of 12 (95% confidence in-
terval [CI], 8-26) for acamprosate and 20 
(95% CI, 11-500) for naltrexone. Oral naltrexone 
(50 mg/d) also decreased return to heavy 
drinking (NNT=12; 95% CI, 8-26), while 
acamprosate did not. Neither medication 
showed a decrease in heavy drinking days. In 
a post hoc subgroup analysis of acamprosate 
for return to any drinking, the drug appeared 
to be more effective in studies with a higher 
risk of bias and less effective in studies with a 
lower risk of bias; the 2 studies with the low-
est risk of bias found no significant effect.
Disulfiram had no effect on any of the 
drinking outcomes analyzed.
Of the off-label medications, topira-
mate showed a decrease in drinking days 
(weighted mean difference [WMD]=-6.5%; 
95% CI, -12.0% to -1.0%), heavy drinking days 
(WMD=-9.0%; 95% CI, -15.3% to -2.7%), and 
drinks per drinking day (WMD=-1.0; 95% CI, 
-1.6 to -0.48).
There were no significant differences in 
health outcomes for any of the medications. 
Adverse events were greater in treatment 
groups than placebo groups. Acamprosate 
was associated with increased risk of diar-
rhea (number needed to harm [NNH]=11; 
95% CI, 6-34), vomiting (NNH=42; 95% CI, 
24-143), and anxiety (NNH=7; 95% CI, 5-11). 
Naltrexone was associated with increased 
risk of nausea (NNH=9; 95% CI, 7-14), vomit-
ing (NNH=24; 95% CI, 17-44), and dizziness 
(NNH 16; 95% CI, 12-28).
WHAT’S NEW
Consider prescribing naltrexone  
to prevent relapse
While previous studies suggested that phar-
macotherapy could help patients with AUD 
remain abstinent, this methodologically rig-
orous meta-analysis compared the efficacy 
of several commonly used medications and 
found clear evidence favoring oral naltrex-
one. Prescribe oral naltrexone 50 mg/d to 
help patients with moderate to severe AUD 
avoid returning to any drinking or heavy 
drinking after alcohol detoxification. Acam-
prosate may also decrease return to drinking, 
although the evidence is not as strong (the 
studies with low bias showed no effect).
CAVEATS
Medication should be used  
with psychosocial treatments
Pharmacotherapy for AUD should be re-
served for patients who want to quit drinking 
and used in conjunction with psychoso-
cial intervention.3 Only one of the studies 
analyzed by Jonas et al1 was conducted in 
primary care. That said, many of the psy-
chosocial interventions—such as regular 
follow-up visits to encourage adherence and 
monitor for adverse effects, in conjunction 
with attendance at Alcoholics Anonymous 
meetings—could be done in primary care 
settings. 
Comorbidities may limit therapy op-
tions. Naltrexone is contraindicated in acute 
hepatitis and liver failure, and in combina-
tion with opioids.5 Acamprosate is contrain-
dicated in renal disease.5 
CHALLENGES TO IMPLEMENTATION
Cost, adherence may be factors  
for some patients 
Perhaps the greatest hurdle in pharmaco-
therapy for AUD in primary care is a lack of 
familiarity with these medications. For phy-
sicians who are comfortable with prescribing 
these medications, implementation may be 
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hindered by a lack of available psychosocial 
resources for successful abstinence. 
Additionally, the medications are ex-
pensive. The branded version of naltrexone 
50 mg costs approximately $118 for a 30-day 
supply,6 and the branded version of acam-
prosate costs approximately $284 for a 30-day 
supply.7
As is the case with any chronic medical 
condition, medication adherence is a chal-
lenge. Naltrexone is taken once daily, while 
acamprosate is taken 3 times a day. The risk 
of relapse is high until 6 to 12 months of so-
briety and then wanes over several years.5 The 
NIAAA recommends treatment for a mini-
mum of 3 months.5                              JFP
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